KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Finished Goods (2016 - 2025)

Astrazeneca (AZN) has 3 years of Finished Goods data on record, last reported at $1.9 billion in Q4 2025.

  • For Q4 2025, Finished Goods rose 26.76% year-over-year to $1.9 billion; the TTM value through Dec 2025 reached $1.9 billion, up 26.76%, while the annual FY2025 figure was $1.9 billion, 26.76% up from the prior year.
  • Finished Goods reached $1.9 billion in Q4 2025 per AZN's latest filing, up from $1.5 billion in the prior quarter.
  • Across five years, Finished Goods topped out at $1.9 billion in Q4 2025 and bottomed at $1.5 billion in Q4 2024.
  • Average Finished Goods over 3 years is $1.7 billion, with a median of $1.6 billion recorded in 2023.
  • Peak YoY movement for Finished Goods: fell 3.25% in 2024, then increased 26.76% in 2025.
  • A 3-year view of Finished Goods shows it stood at $1.6 billion in 2023, then fell by 3.25% to $1.5 billion in 2024, then rose by 26.76% to $1.9 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $1.9 billion in Q4 2025, $1.5 billion in Q4 2024, and $1.6 billion in Q4 2023.